AnaptysBio, Inc. (NASDAQ:ANAB) Receives $41.45 Consensus Target Price from Analysts

Shares of AnaptysBio, Inc. (NASDAQ:ANAB) have been assigned an average rating of “Moderate Buy” from the twelve ratings firms that are covering the firm, Marketbeat reports. Four equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $41.45.

A number of analysts recently issued reports on ANAB shares. Wells Fargo & Company decreased their price objective on AnaptysBio from $56.00 to $40.00 and set an “overweight” rating on the stock in a research note on Thursday, December 12th. BTIG Research downgraded shares of AnaptysBio from a “buy” rating to a “neutral” rating in a report on Monday, December 2nd. JPMorgan Chase & Co. reduced their price objective on shares of AnaptysBio from $66.00 to $36.00 and set an “overweight” rating for the company in a research note on Thursday, December 19th. Truist Financial lowered their target price on shares of AnaptysBio from $30.00 to $20.00 and set a “hold” rating on the stock in a research note on Wednesday, December 18th. Finally, HC Wainwright lowered shares of AnaptysBio from a “buy” rating to a “neutral” rating and reduced their price target for the company from $52.00 to $19.00 in a research report on Wednesday, December 11th.

Insider Transactions at AnaptysBio

In other AnaptysBio news, Director Ecor1 Capital, Llc acquired 6,646 shares of the business’s stock in a transaction dated Thursday, January 2nd. The stock was bought at an average price of $12.95 per share, with a total value of $86,065.70. Following the purchase, the director now owns 7,880,094 shares of the company’s stock, valued at approximately $102,047,217.30. This trade represents a 0.08 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 33.70% of the company’s stock.

Hedge Funds Weigh In On AnaptysBio

A number of large investors have recently added to or reduced their stakes in ANAB. Bank of New York Mellon Corp grew its stake in shares of AnaptysBio by 16.3% during the second quarter. Bank of New York Mellon Corp now owns 74,510 shares of the biotechnology company’s stock valued at $1,867,000 after buying an additional 10,423 shares during the last quarter. Rhumbline Advisers increased its stake in AnaptysBio by 1.8% in the 2nd quarter. Rhumbline Advisers now owns 29,715 shares of the biotechnology company’s stock worth $745,000 after purchasing an additional 525 shares during the period. TD Asset Management Inc lifted its position in AnaptysBio by 67.3% in the second quarter. TD Asset Management Inc now owns 37,800 shares of the biotechnology company’s stock valued at $947,000 after purchasing an additional 15,200 shares during the last quarter. Headlands Technologies LLC lifted its position in AnaptysBio by 444.8% in the second quarter. Headlands Technologies LLC now owns 3,552 shares of the biotechnology company’s stock valued at $89,000 after purchasing an additional 2,900 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its stake in shares of AnaptysBio by 52.4% during the second quarter. Renaissance Technologies LLC now owns 152,702 shares of the biotechnology company’s stock valued at $3,827,000 after purchasing an additional 52,502 shares during the period.

AnaptysBio Stock Performance

ANAB stock opened at $14.21 on Monday. The stock has a fifty day moving average of $18.67 and a 200-day moving average of $28.19. AnaptysBio has a fifty-two week low of $12.51 and a fifty-two week high of $41.31. The company has a market capitalization of $432.40 million, a price-to-earnings ratio of -2.34 and a beta of -0.02.

AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($1.14) EPS for the quarter, topping the consensus estimate of ($1.72) by $0.58. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. The company had revenue of $30.02 million during the quarter, compared to the consensus estimate of $7.92 million. Equities analysts predict that AnaptysBio will post -6.02 EPS for the current year.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.